Biosolution Co.Ltd - Asset Resilience Ratio

Latest as of September 2025: 0.34%

Biosolution Co.Ltd (086820) has an Asset Resilience Ratio of 0.34% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Biosolution Co.Ltd for a breakdown of total debt and financial obligations.

Liquid Assets

₩211.66 Million
≈ $143.44K USD Cash + Short-term Investments

Total Assets

₩62.56 Billion
≈ $42.40 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how Biosolution Co.Ltd's Asset Resilience Ratio has changed over time. See Biosolution Co.Ltd shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Biosolution Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 086820 stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩211.66 Million 0.34%
Total Liquid Assets ₩211.66 Million 0.34%

Asset Resilience Insights

  • Limited Liquidity: Biosolution Co.Ltd maintains only 0.34% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Biosolution Co.Ltd Industry Peers by Asset Resilience Ratio

Compare Biosolution Co.Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Fortress Biotech Inc
NASDAQ:FBIO
Biotechnology 11.59%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 0.00%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Apellis Pharmaceuticals Inc
NASDAQ:APLS
Biotechnology 0.58%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
BrightGene Bio Medical Technology C
SHG:688166
Biotechnology 1.00%
BioArctic AB (publ)
ST:BIOA-B
Biotechnology 72.35%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%

Annual Asset Resilience Ratio for Biosolution Co.Ltd (2015–2024)

The table below shows the annual Asset Resilience Ratio data for Biosolution Co.Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 21.27% ₩14.35 Billion
≈ $9.72 Million
₩67.46 Billion
≈ $45.72 Million
-19.56pp
2023-12-31 40.83% ₩37.71 Billion
≈ $25.56 Million
₩92.35 Billion
≈ $62.58 Million
-38.53pp
2022-12-31 79.36% ₩72.80 Billion
≈ $49.34 Million
₩91.73 Billion
≈ $62.16 Million
-8.65pp
2021-12-31 88.01% ₩83.08 Billion
≈ $56.30 Million
₩94.40 Billion
≈ $63.98 Million
+15.31pp
2020-12-31 72.70% ₩36.20 Billion
≈ $24.54 Million
₩49.80 Billion
≈ $33.75 Million
-5.43pp
2019-12-31 78.13% ₩40.48 Billion
≈ $27.43 Million
₩51.81 Billion
≈ $35.11 Million
-6.71pp
2018-12-31 84.85% ₩44.85 Billion
≈ $30.40 Million
₩52.87 Billion
≈ $35.83 Million
+54.06pp
2017-12-31 30.79% ₩2.27 Billion
≈ $1.54 Million
₩7.38 Billion
≈ $5.00 Million
+1.51pp
2016-12-31 29.27% ₩2.58 Billion
≈ $1.75 Million
₩8.82 Billion
≈ $5.98 Million
-1.40pp
2015-12-31 30.67% ₩3.01 Billion
≈ $2.04 Million
₩9.80 Billion
≈ $6.64 Million
--
pp = percentage points

About Biosolution Co.Ltd

KQ:086820 Korea Biotechnology
Market Cap
$196.07 Million
₩289.33 Billion KRW
Market Cap Rank
#16612 Global
#711 in Korea
Share Price
₩11990.00
Change (1 day)
+8.02%
52-Week Range
₩7390.00 - ₩34950.00
All Time High
₩62300.00
About

Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide. The company offers CartiLife, an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects; KeraHeal-Allo, a thermosensitive hydrogel-type allogenic keratinocyte cell-therapy product to promote re-epithelialization of deep 2… Read more